Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 8, 2022
September 13, 2022
eedd66d7-1c8a-4071-8ce6-a53c3f8790a3
Related Documents
Clinical Pharmacology Considerations for Peptide Drug Products
Guidance DocumentDecember 14, 2023Center for Drug Evaluation and Research
Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs
Guidance DocumentApril 29, 2024Center for Drug Evaluation and Research
Innovative Approaches for Nonprescription Drug Products
Guidance DocumentJuly 18, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.